HK1247122A1 - 組合及其用途 - Google Patents

組合及其用途

Info

Publication number: HK1247122A1
Authority: HK; Hong Kong
Prior art keywords: combinations
Prior art date: 2015-08-21

Application number

HK18106849.0A

Other languages

English (en)

Inventor

J‧恩德爾

M‧溫德爾里奇

R‧博克斯哈默

Original Assignee

莫佛塞斯公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-21

Filing date

2018-05-25

Publication date

2018-09-21

2018-05-25 Application filed by 莫佛塞斯公司 filed Critical 莫佛塞斯公司

2018-09-21 Publication of HK1247122A1 publication Critical patent/HK1247122A1/zh

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Ultra Sonic Daignosis Equipment (AREA)

HK18106849.0A 2015-08-21 2018-05-25 組合及其用途 HK1247122A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP15181925		2015-08-21
PCT/EP2016/069571 WO2017032679A1 (en)	2015-08-21	2016-08-18	Combinations and uses thereof

Publications (1)

Publication Number	Publication Date
HK1247122A1 true HK1247122A1 (zh)	2018-09-21

Family

ID=54010888

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18106849.0A HK1247122A1 (zh)	2015-08-21	2018-05-25	組合及其用途

Country Status (24)

Country	Link
US (2)	US11224654B2 (zh)
EP (2)	EP3954388A1 (zh)
JP (3)	JP6862422B2 (zh)
KR (2)	KR20240052084A (zh)
CN (2)	CN115054697A (zh)
AU (3)	AU2016311136B2 (zh)
BR (1)	BR112018003263A2 (zh)
CA (1)	CA2995738A1 (zh)
CY (1)	CY1124706T1 (zh)
DK (1)	DK3337506T3 (zh)
ES (1)	ES2891336T3 (zh)
HK (1)	HK1247122A1 (zh)
HR (1)	HRP20211291T1 (zh)
HU (1)	HUE056408T2 (zh)
IL (2)	IL257345B2 (zh)
LT (1)	LT3337506T (zh)
MX (2)	MX2018002241A (zh)
PL (1)	PL3337506T3 (zh)
PT (1)	PT3337506T (zh)
RS (1)	RS62260B1 (zh)
RU (1)	RU2767063C2 (zh)
SI (1)	SI3337506T1 (zh)
WO (1)	WO2017032679A1 (zh)
ZA (1)	ZA201801052B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3630177B1 (en)	2017-05-31	2023-08-09	MorphoSys AG	Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2019011918A1 (en)	2017-07-10	2019-01-17	International - Drug - Development - Biotech	TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200030337A (ko) *	2018-09-12	2020-03-20	주식회사 녹십자랩셀	종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
US20220241411A1 (en) *	2020-11-30	2022-08-04	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4708871A (en)	1983-03-08	1987-11-24	Commonwealth Serum Laboratories Commission	Antigenically active amino acid sequences
US5686072A (en)	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US6518277B1 (en)	2000-04-25	2003-02-11	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
MXPA03002262A (es)	2000-09-18	2003-10-15	Idec Pharma Corp	Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
EP1461423B1 (en)	2001-12-03	2008-05-14	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
US20080152649A1 (en) *	2002-03-01	2008-06-26	Xencor, Inc.	Optimized igf-1r antibodies and methods of using the same
WO2005012493A2 (en)	2003-07-31	2005-02-10	Immunomedics, Inc.	Anti-cd19 antibodies
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
RS55551B1 (sr)	2004-05-13	2017-05-31	Icos Corp	Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
WO2007002223A2 (en)	2005-06-20	2007-01-04	Medarex, Inc.	Cd19 antibodies and their uses
DK2270050T3 (da)	2005-12-30	2013-08-12	Merck Patent Gmbh	Anti-CD19-antistoffer med nedsat immunogenicitet
AU2007285976B2 (en) *	2006-08-14	2011-08-18	Xencor, Inc	Optimized antibodies that target CD19
MX2009002414A (es)	2006-09-08	2009-05-20	Medimmune Llc	Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
WO2008150494A1 (en)	2007-05-30	2008-12-11	Xencor, Inc.	Methods and compositions for inhibiting cd32b expressing cells
US7968687B2 (en)	2007-10-19	2011-06-28	Seattle Genetics, Inc.	CD19 binding agents and uses thereof
EA201190132A1 (ru)	2009-02-23	2013-01-30	Гленмарк Фармасьютикалс С.А.	Гуманизированные антитела, связывающиеся с cd19, и их применение
CA2765080C (en)	2009-06-24	2018-07-17	The Feinstein Institute For Medical Research	Methods for treating chronic lymphocytic leukemia
JP6092625B2 (ja) *	2009-10-27	2017-03-08	アムゲンリサーチ（ミュンヘン）ゲーエムベーハー	ＣＤ１９ｘＣＤ３二重特異性抗体を投与するための投与計画
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
TWI545134B (zh) *	2010-10-22	2016-08-11	西雅圖遺傳學公司	以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴｍＴＯＲ路徑抑制劑間的協同功效
EP2524929A1 (en)	2011-05-17	2012-11-21	Sanofi	Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2744826B1 (en) *	2011-08-16	2022-02-09	MorphoSys AG	Combination therapy with an anti-cd19 antibody and a purine analog
PT2744515T (pt) *	2011-08-16	2022-05-19	Morphosys Ag	Terapia de combinação com um anticorpo anti-cd19 e uma mostarda de nitrogénio
MX2014010656A (es)	2012-03-05	2015-03-03	Gilead Calistoga Llc	Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluo ro-3-fenilquinazolin-4(3h)-ona.
WO2014126928A1 (en)	2013-02-15	2014-08-21	3M Innovative Properties Company	System and method for making pleated filter media

2016
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 CN CN202210502807.XA patent/CN115054697A/zh active Pending
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 MX MX2018002241A patent/MX2018002241A/es unknown
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en active Application Filing
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 KR KR1020247011695A patent/KR20240052084A/ko not_active Application Discontinuation
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Application Discontinuation
- 2016-08-18 BR BR112018003263A patent/BR112018003263A2/pt active Search and Examination
- 2016-08-18 IL IL297057A patent/IL297057A/en unknown
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
- 2018-05-25 HK HK18106849.0A patent/HK1247122A1/zh unknown
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-08-11 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US20220088197A1/en active Pending
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en active Pending

Also Published As

Publication number	Publication date
JP2023093495A (ja)	2023-07-04
IL257345B (en)	2022-11-01
CA2995738A1 (en)	2017-03-02
RU2767063C2 (ru)	2022-03-16
MX2018002241A (es)	2018-03-23
AU2024202109A1 (en)	2024-05-02
AU2022202800A1 (en)	2022-05-19
ES2891336T3 (es)	2022-01-27
JP2021113194A (ja)	2021-08-05
LT3337506T (lt)	2021-10-11
CN115054697A (zh)	2022-09-16
JP2018523685A (ja)	2018-08-23
HRP20211291T1 (hr)	2021-12-10
AU2016311136A1 (en)	2018-03-01
CY1124706T1 (el)	2022-07-22
RU2018107929A3 (zh)	2020-01-14
EP3954388A1 (en)	2022-02-16
US20180228893A1 (en)	2018-08-16
EP3337506A1 (en)	2018-06-27
RU2018107929A (ru)	2019-09-23
PT3337506T (pt)	2021-09-24
RS62260B1 (sr)	2021-09-30
ZA201801052B (en)	2021-05-26
BR112018003263A2 (pt)	2018-09-25
US20220088197A1 (en)	2022-03-24
IL257345B2 (en)	2023-03-01
WO2017032679A1 (en)	2017-03-02
EP3337506B1 (en)	2021-07-21
IL297057A (en)	2022-12-01
KR20240052084A (ko)	2024-04-22
US11224654B2 (en)	2022-01-18
CN107921129A (zh)	2018-04-17
SI3337506T1 (sl)	2021-12-31
CN107921129B (zh)	2022-05-27
KR20180042335A (ko)	2018-04-25
MX2022006154A (es)	2022-10-07
AU2016311136B2 (en)	2022-02-17
JP6862422B2 (ja)	2021-04-21
PL3337506T3 (pl)	2022-01-03
IL257345A (en)	2018-03-29
DK3337506T3 (da)	2021-09-06
AU2022202800B2 (en)	2024-01-04
HUE056408T2 (hu)	2022-02-28

Publication	Publication Date	Title
HK1243741A1 (zh)	2018-07-20	腫瘤壞死因子受體超家族(tnfrsf)結合劑
IL255577B (en)	2022-02-01	Binding materials - tigit and their uses
HK1231471A1 (zh)	2017-12-22	-雜芳氧基-和芳氧基-喹啉- -甲酰胺及其用途
IL252216A0 (en)	2017-07-31	Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
PL3152226T3 (pl)	2019-10-31	Modyfikowane cyklopentapeptydy i ich zastosowania
SG11201706029VA (en)	2017-08-30	Anti-senescence compounds and uses thereof
HK1246780A1 (zh)	2018-09-14	氮雜-吡啶酮化合物及其用途
ZA201705456B (en)	2019-10-30	Benzoxaborole compounds and uses thereof
GB201504763D0 (en)	2015-05-06	Compounds and uses
HK1247122A1 (zh)	2018-09-21	組合及其用途
IL254241A0 (en)	2017-10-31	Etv2 and its uses
HK1250915A1 (zh)	2019-01-18	組合物和其用途
IL253459A0 (en)	2017-09-28	Isoergoline compounds and their uses
GB201718875D0 (en)	2017-12-27	Autophagy-inhibiting compounds and uses thereof
GB2543375B (en)	2020-01-22	Compounds and their uses
GB2545167B (en)	2022-02-16	Cloches and use thereof
GB201500278D0 (en)	2015-02-25	Novel combination and use
GB201404728D0 (en)	2014-04-30	Disc-over incorporating disc-heads and disc-earning